News & Events
Published On: 2/13/2019
TARGET PharmaSolutions Launches TARGET-DERM Real-World Observational Study to Advance the Understanding of Atopic Dermatitis (Eczema) and Other Immune-Mediated Inflammatory Skin Conditions
TARGET PharmaSolutions, Inc., a company focused on real-world evidence, announced today that it launched its latest large-scale observational study, TARGET-DERM (NCT03661866). The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions (IMISCs), initially focusing on patients with atopic dermatitis (AD/eczema). TARGET-DERM’s first participant enrolled on January 25, 2019. The trial will enroll up to 15,000 participants, including adult and pediatric patients, at up to 100 sites in the United States, Canada and Europe. TARGET-DERM will eventually include the skin conditions hidradenitis suppurativa (painful bumps under the skin), alopecia areata (autoimmune-related hair loss), and vitiligo (loss of skin pigment).
TARGET-DERM will create a research registry of patients with immune-mediated inflammatory skin conditions within academic and community real-world practices to assess the safety and effectiveness of current and future therapies. TARGET-DERM is led by an academic steering committee chaired by Emma Guttman-Yassky, MD, The Sol and Clara Kest Professor of Dermatology and Immunology, and Vice Chair, department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, and Diamant Thaçi, MD,Professor and Head, Comprehensive Center for Inflammation Medicine, University of Lubeck, Germany.
“We are excited to initiate enrollment and to advance the important work of further understanding inflammatory skin diseases and particularly AD, through this TARGET-DERM registry,” said Dr. Guttman-Yassky. “There are many critical, unanswered questions regarding the mechanisms underlying eczema and these other complex immune-mediated skin conditions. TARGET-DERM is a unique opportunity to better understand the natural history of AD and other diseases and to evaluate different treatment regimens, outcomes and adverse events across a large, diverse patient population. It is our hope that this research can better inform how these conditions are approached and ultimately improve the lives of the millions of people who suffer from them.”
The TARGET-DERM study design is disease-focused, not treatment-specific, allowing for continuous acquisition of natural history and outcomes data. This includes patient reported outcomes (PROs), as new treatments enter the market and clinical programs evolve. TARGET-DERM will collect three years of retrospective data and five years of prospective data on its participants. This data will also be connected to an extensive biorepository which TARGET-DERM stakeholders can access for genomic studies and translational research.
Information about the TARGET-DERM trial, including enrollment information, can be found here.
TARGET-DERM is the sixth disease category spearheaded by TARGET PharmaSolutions since 2015. Ongoing real-world TARGET studies include nonalcoholic steatohepatitis (TARGET-NASH), hepatocellular carcinoma (TARGET-HCC), inflammatory bowel disease (TARGET-IBD), primary biliary cholangitis (TARGET-PBC) and chronic hepatitis B (TARGET-HBV).
The TARGET model organizes a community of stakeholders, including key scientific leaders, regulatory agencies, pharmaceutical manufacturers, and patient advocacy groups, around a specific disease to generate real-world evidence about the natural history of the given disease, current treatment paradigm, and patient outcomes. This model enables TARGET’s stakeholders to answer critical strategic and planning questions. TARGET PharmaSolutions also provides regulatory-grade data and analysis that may be used throughout the pharmaceutical development and commercialization process, including expanded indications and fulfillment of post-market studies.
About Target RWE
Headquartered in Durham, NC, Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care.
Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data (RWD) from a large network of participating sites (academic and community) across the United States, Europe and other non-U.S. locations. Target RWE’s datasets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases. Whether partners need consulting services, datasets, support for custom solutions or access to a large biorepository of disease agnostic patient samples, Target RWE strives to be the preferred choice.
For more information, visit www.targetrwe.com.
984.234.0268 ext 205
07/22/2021Target RWE HBV Research on Antiviral Treatments, Characteristics, and Clinical Outcomes Published in Digestive Diseases and Sciences
06/29/2021Liver International Publishes Hepatocellular Carcinoma RWE Review
06/22/2021Target RWE Study Shows Significant Differences in Medication Use Among Older Patients with IBD Compared to Younger Patients
06/15/2021TARGET-NASH Study Finds Statins Underutilized in Patients with NAFLD and At-Risk of Heart Disease
05/25/2021Target RWE COVID-19 Data: Real-World Evidence Analysis Shows 3.6% of COVID-19 Hospitalized Patients Discharged Alive Required Readmission